Pathos AI will apply its Foundry platform to Tempus AI's neurological dataset to track patient outcomes and speed research into Alzheimer's disease biology.

Overview Debates Related claims Topics Sources

UCLA investigators developed MAESTRO, an artificial intelligence platform using large language models to analyze scientific knowledge and identify drug combinations that overcome cancer treatment resistance.

The strategic agreements mark Pathos AI's expansion from oncology into neurological conditions, beginning with Alzheimer's disease treatments.

Pathos AI agreed to license up to 500,000 de-identified patient records for Alzheimer's or neurological conditions from Tempus AI under a five-year agreement worth up to $55 million, at 100,000 records per year.

Pathos AI's Foundry platform operates thousands of AI agents that calculate the probability of success for clinical assets by analyzing clinical data, genomics, biological specimen data, and market competition.

Pathos AI entered into a strategic collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological conditions.

MAESTRO evaluates potential drug pairings, ranks promising candidates, and generates testable biological explanations without relying on vast amounts of experimental training data.

To identify drug candidates, UCLA researchers supplied MAESTRO with scientific data on prostate cancer biology, resistance mechanisms, and known drug actions.

An international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London, developed an artificial intelligence tool called iPhenMap to create biological maps of tumors.

The iPhenMap artificial intelligence tool integrated genetic, metabolic, protein, epigenetic, single-cell, and clinical data from 2,000 patient tumor samples to uncover hidden cellular mechanisms.

Bristol Myers Squibb agreed to make fixed payments totaling $137.5 million through 2031 under a Statement of Work with Tempus AI for oncology data and analytic services.

Pathos AI's proprietary software platform Foundry has access to approximately 200 petabytes of oncological data to generate and test hypotheses on disease biology.

A side letter agreement between Tempus AI, Pathos AI, and Bristol Myers Squibb restricts Tempus AI from licensing its neurology records to other parties for a specified period.

Machine-learning antibody profiles differentiated individuals who later developed complicated Crohn's disease from non-complicated Crohn's disease up to approximately 10 years before diagnosis with an AUC value of 0.85.

Machine-learning models integrating early antibody signatures discriminated individuals who would later develop Crohn's disease or ulcerative colitis from healthy controls up to 10 years before diagnosis, with AUC values of 0.90 and 0.84, respectively.

Early Alzheimer's symptoms such as hearing impairment can reduce engagement in physical activity, triggering accelerated cognitive and memory decline.

A UK study of 1,139 people over age 50 found that moderate to vigorous physical activity reduced dementia risk by 34% to 50% over eight to ten years.

Study co-author Dr. You Zhou stated that combining gut bacteria and digestive chemicals distinguished individuals with mild cognitive impairment from healthy people with high accuracy.

Brain health benefits against Alzheimer's tau protein accumulation appeared at 3,000 steps daily, with an optimal protective plateau between 5,000 and 7,500 steps daily.

A study tracking almost 300 older adults found that physical activity did not reduce toxic amyloid plaques, but reduced signs of dementia by almost half in more active participants.

In older adults with early brain signs of Alzheimer's, physical activity reduced the accumulation of misfolded tau proteins in specific brain areas over nine to 11 years, according to a study tracking participants with pedometers.